Key facts
- This page summarizes James E. Brown's Form 4 filing for DURECT CORP (DRRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Feb 2023, 12:19.
James E. Brown - 21 Feb 2023 Form 4 Insider Report for DURECT CORP (DRRX)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- DRRX
- Reported as of
- 21 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Feb 2023, 12:19:12 UTC
- Prior SEC filing
- 10 Jan 2022
- Next SEC filing
- 06 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ James E. Brown
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Brown filed Form 4 for DURECT CORP (DRRX) on 23 Feb 2023.
Change
- Previous filing in this sequence was filed on 10 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DRRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 21 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $5.07
- Footnotes
- F1
DRRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +50,665
- Change %
- Price
- $0.000000
- Shares after
- 50,665
- Date
- 21 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,665
- Exercise price
- $5.07
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option will vest and become exercisable in installments of one-sixteenth (1/16) of the total number of shares at the end of each three month period following the grant date, subject to the Reporting Person providing continuous service to the Issuer through the applicable vesting date.
Footnote F2
The option is fully vested and immediately exercisable.